Dr Nizar Bahlis speaks to ecancer at ASH 2018 about the results of the TOURMALINE-MM1 study and the use of proteasome inhibitors.
He explains that the study compares lenalidomide‑dexamethasone with a combination of lenalidomide‑dexamethasone and ixazomib in relapsed/refractory multiple myeloma patients with the combination arm superior in showing improving progression free survival.
Dr Bahlis acknowledges the importance of the NF-κB pathway and that patients with an activated non-canonical NF-κB pathway saw the best benefit from the ixazomib and lenalidomide‑dexamethasone combination.
He also discusses the use proteasome inhibitors (PIs) as a treatment for multiple myeloma patients and the benefit of PI maintenance.
This programme has been supported by an unrestricted educational grant from Takeda.